Tolera Therapeutics Inc., a Kalamazoo, Michigan-based biotechnology company focusing on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets, has closed its $5.5m Series B-3 financing.
The company intends to use the capital to prepare for Phase 3 investigation of TOL101, their lead clinical candidate. Tolera intends to submit a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial comparing TOL101 to Thymoglobulin, the current market leading induction agent, for prevention of acute organ rejection.
Led by CEO John Puisis, Tolera focuses on commercializing its therapeutic monoclonal antibody technology for the transplantation market. It builds upon research done at the University of Kentucky and the Cleveland Clinic.